I'm also surprised that Abbvie didn't list their drugs. Is it possible that they can still do so prior to March, Mallani? In the attachment, it notes that consumers will have an opportunity to comment on changes to listings. Does that mean they can request additional listings of other new drugs?
It certainly is not humane right that people should have to struggle through 24-48 weeks with those protease inhibitors plus the additional needed drugs, when newer, gentler treatments exist....and for a shorter duration with higher rates of SVR. I really hope that Harvoni and Sovaldi are approved there. That would truly be a great thing!
mallani said
Jan 10, 2015
Hi all,
The March meeting of the PBAC here, will be the busiest for some time. This will decide whether some DAA HepC treatments are made available to Australians. The drugs are:
Sunvepra (Asunaprevir)
Daklinza (Daclatasvir)
Harvoni (Sovaldi/Ledipasvir)
Sovaldi
A brief look at the Australian Forum recently showed members were still struggling through triple for 24 or 48 weeks, mostly with Olysio or Victrelis.
It's surprising that AbbVie haven't listed their drugs. At best, we can only hope that Sovaldi will be approved. The lobbying has been intense but we remain a nation with no spare cash. The plunging coal and iron ore price has adversely affected our national earnings.
I'm also surprised that Abbvie didn't list their drugs. Is it possible that they can still do so prior to March, Mallani? In the attachment, it notes that consumers will have an opportunity to comment on changes to listings. Does that mean they can request additional listings of other new drugs?
It certainly is not humane right that people should have to struggle through 24-48 weeks with those protease inhibitors plus the additional needed drugs, when newer, gentler treatments exist....and for a shorter duration with higher rates of SVR. I really hope that Harvoni and Sovaldi are approved there. That would truly be a great thing!
Hi all,
The March meeting of the PBAC here, will be the busiest for some time. This will decide whether some DAA HepC treatments are made available to Australians. The drugs are:
Sunvepra (Asunaprevir)
Daklinza (Daclatasvir)
Harvoni (Sovaldi/Ledipasvir)
Sovaldi
A brief look at the Australian Forum recently showed members were still struggling through triple for 24 or 48 weeks, mostly with Olysio or Victrelis.
It's surprising that AbbVie haven't listed their drugs. At best, we can only hope that Sovaldi will be approved. The lobbying has been intense but we remain a nation with no spare cash. The plunging coal and iron ore price has adversely affected our national earnings.
http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/agenda/pdf/pbac-meeting-agenda-march-2015.pdf